Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)

NCT04121403 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

267

Enrollment

OTHER

Sponsor class

Conditions

Relapsing Multiple Sclerosis
Multiple Sclerosis

Interventions

BIOLOGICAL: Rituximab
DRUG: Cladribine

Sponsor

Oslo University Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]